Renovaro BioSciences Welcomes GEDiCube Announcement of New Joint Effort
August 30, 2023 09:15 ET
|
Renovaro Biosciences Inc.
LOS ANGELES, Aug. 30, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro BioSciences congratulates GEDiCube on their joint effort to work to accelerate early diagnosis of cancer in clinical trials. ...
Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical Officer
August 21, 2023 09:15 ET
|
Renovaro Biosciences Inc.
LOS ANGELES, Aug. 21, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro BioSciences congratulates GEDi Cube on its appointment of Dr. Lester Russell as Chief Medical Officer. For more information:...
AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer
August 09, 2023 09:00 ET
|
Renovaro Biosciences Inc.
Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer In silico detection for 12 additional cancers, including pancreaticMore than 2,600 proprietary...
Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting
June 23, 2023 17:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise...
Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
June 08, 2023 08:45 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application...
Enochian BioSciences’ CEO Letter to Shareholders
April 03, 2023 09:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Accelerated Pre-Investigational New Drug (Pre-IND) submission to the US Food and Drug Administration (FDA) for potential cancer...
Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher
March 29, 2023 09:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy...
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements
March 13, 2023 08:30 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual...
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022
February 23, 2023 16:04 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Feb. 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On February 16, 2023, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC...
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022
November 30, 2022 17:20 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On November 23, 2022, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC...